

Attorney Docket No.: ISPH-0827  
Inventors: Bennett and Freier  
Serial No.: 10/772,542  
Filing Date: February 5, 2004  
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding HKR1, wherein said compound comprises at least an 8 nucleobase portion of SEQ ID NO:56 and which specifically hybridizes with said nucleic acid molecule encoding HKR1 and inhibits the expression of HKR1.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Attorney Docket No.: ISPH-0827  
Inventors: Bennett and Freier  
Serial No.: 10/772,542  
Filing Date: February 5, 2004  
Page 3

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (original): A method of inhibiting the expression of HKR1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of HKR1 is inhibited.